Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.

Abstract:

BACKGROUND:The urgent need for castration-resistant prostate cancer molecular characterization to guide treatment has been constrained by the disease's predilection to metastasize primarily to bone. We hypothesized that the use of clinical and imaging criteria could maximize tissue acquisition from bone marrow biopsies (BMBs). We aimed to develop a score for the selection of patients undergoing BMB. MATERIALS AND METHODS:A total of 115 BMBs were performed in 101 patients: 57 were included in a derivation set and 58 were used as the validation set. The clinical and laboratory data and prebiopsy computed tomography parameters (Hounsfield units [HUs]) were determined. A score for the prediction of biopsy positivity was developed from logistic regression analysis of the derivation set and tested in the validation set. RESULTS:Of the 115 biopsy specimens, 75 (62.5%) were positive; 35 (61.4%) in the test set and 40 (69%) in the validation set. On univariable analysis, hemoglobin (P = .019), lactate dehydrogenase (P = .003), prostate-specific antigen (P = .005), and mean HUs (P = .004) were selected. A score based on the LDH level (≥ 225 IU/L) and mean HUs (≥ 125) was developed in multivariate analysis and was associated with BMB positivity in the validation set (odds ratio, 5.1; 95% confidence interval, 1.9%-13.4%; P = .001). The area under the curve of the score was 0.79 in the test set and 0.77 in the validation set. CONCLUSION:BMB of the iliac crest is a feasible technique for obtaining tumor tissue for genomic analysis in patients with castration-resistant prostate cancer metastatic to the bone. A signature based on the mean HUs and LDH level can predict a positive yield with acceptable internal validity. Prospective studies of independent cohorts are needed to establish the external validity of the score.

journal_name

Clin Genitourin Cancer

authors

Lorente D,Omlin A,Zafeiriou Z,Nava-Rodrigues D,Pérez-López R,Pezaro C,Mehra N,Sheridan E,Figueiredo I,Riisnaes R,Miranda S,Crespo M,Flohr P,Mateo J,Altavilla A,Ferraldeschi R,Bianchini D,Attard G,Tunariu N,de Bono J

doi

10.1016/j.clgc.2016.04.016

subject

Has Abstract

pub_date

2016-12-01 00:00:00

pages

485-493

issue

6

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(16)30106-9

journal_volume

14

pub_type

杂志文章
  • Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.

    abstract:BACKGROUND:The objective of this study was to investigate positive surgical margin (PSM) rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess PSM impact on cancer-specific mortality (CSM). PATIENTS AND METHODS:Within the Surveillance, Epidemiology, and End Results (SEER) database (...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2018.09.024

    authors: Preisser F,Mazzone E,Knipper S,Nazzani S,Bandini M,Shariat SF,Tian Z,Saad F,Montorsi F,Zorn KC,Graefen M,Tilki D,Karakiewicz PI

    更新日期:2019-02-01 00:00:00

  • Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

    abstract:BACKGROUND:Myalgia and arthralgia immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors (CPIs) present a clinical challenge. We describe the clinical characteristics and treatment of myalgia and arthralgia irAEs in CPI-treated patients with genitourinary (GU) malignancies. PATIENTS AND M...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.021

    authors: Ornstein MC,Calabrese C,Wood LS,Kirchner E,Profusek P,Allman KD,Martin A,Kontzias A,Grivas P,Garcia JA,Calabrese LH,Rini BI

    更新日期:2019-06-01 00:00:00

  • Clinical Disparities for Minorities and Foreign-Born Men With Undescended Versus Descended Testicular Germ Cell Tumors.

    abstract:BACKGROUND:Few reports have been published regarding the outcomes of patients who develop an undescended testicular malignancy (UTM). Our objective was to analyze the sociodemographic and survival outcomes of patients with UTM and those of with descended testicular malignancy (DTM). PATIENTS AND METHODS:All 17 registr...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.08.004

    authors: Klaassen Z,Reinstatler L,Wilson SN,Ellington C,Li Q,Terris MK,Moses KA

    更新日期:2016-06-01 00:00:00

  • Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.

    abstract:BACKGROUND:Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2016.03.006

    authors: O'Donnell PH,Alanee S,Stratton KL,Garcia-Grossman IR,Cao H,Ostrovnaya I,Plimack ER,Manschreck C,Ganshert C,Smith ND,Steinberg GD,Vijai J,Offit K,Stadler WM,Bajorin DF

    更新日期:2016-12-01 00:00:00

  • Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

    abstract:INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.007

    authors: Balakrishnan AS,Washington SL 3rd,Meng MV,Porten SP

    更新日期:2019-06-01 00:00:00

  • Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.

    abstract:BACKGROUND:Standard treatments have not been established in metastatic papillary renal-cell carcinoma (PRCC). We aimed to investigate treatment outcomes in patients with mPRCC. PATIENTS AND METHODS:This study included 51 patients who were diagnosed with PRCC at 14 institutions. Pathologic slides were reviewed by patho...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2018.07.028

    authors: Ito K,Mikami S,Tatsugami K,Masumori N,Shinohara N,Kondo T,Nakanishi S,Nagashima Y,Eto M,Kamba T,Kuroda N,Tomita Y,Matsuyama H,Onishi T,Tsushima T,Nakazawa H,Oya M,Ozono S,Naito S,Asano T

    更新日期:2018-12-01 00:00:00

  • Perioperative Outcomes of Open Retrograde Extraperitoneal Versus Intracorporeal Robot-assisted Radical Cystoprostatectomy in Men: A Dual-center Comparative Study.

    abstract:INTRODUCTION:We compared retrograde extraperitoneal open radical cystoprostatectomy (REORC) and robot-assisted radical cystoprostatectomy with intracorporeal diversion (iRARC) and have reported the early perioperative outcomes. PATIENTS AND METHODS:REORC and iRARC were each performed at a different tertiary high-volum...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.006

    authors: Refaai K,Sharafeldin MA,Elabbady A,Sameh W,Thurairaja R,Nair R,Dasgupta P,Khan MS,Mohamed E

    更新日期:2020-06-01 00:00:00

  • Synchronous Bilateral RCC Is Associated With Poor Recurrence-Free Survival Compared With Unilateral RCC: A Single-Center Study With Propensity Score Matching Analysis.

    abstract:BACKGROUND:Understanding the tumorigenesis of bilateral cancers occurring in paired organs is essential for treatment planning and follow-up strategies. To the best of our knowledge, only a few studies compared the survival outcomes in patients with unilateral and bilateral renal cell carcinoma (RCC). We aimed to evalu...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.02.008

    authors: Kim JK,Lee H,Oh JJ,Lee S,Hong SK,Lee SE,Byun SS

    更新日期:2019-06-01 00:00:00

  • Neoadjuvant Radiotherapy Improves Survival in Patients With T2b/T3 Bladder Cancer: A Population-Based Analysis.

    abstract:BACKGROUND:Neoadjuvant radiotherapy (NART) for muscle-invasive bladder cancer (MIBC) is currently underused. However, the outcomes for MIBC have remained suboptimal. We investigated the relationship of NART to cause-specific mortality (CSM) and overall mortality (OM) among patients with a diagnosis of MIBC. MATERIALS ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.02.014

    authors: Diaz DA,Pollack A,Reis IM,Mahmoud O,Gonzalgo ML,Ishkanian A,Fernandez G,Manoharan M,Abramowitz MC

    更新日期:2015-08-01 00:00:00

  • Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.

    abstract::Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA t...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.036

    authors: Sonpavde G,Aparicio A,Guttierez I,Boehm KA,Hutson TE,Berry WR,Asmar L,von Hoff DD

    更新日期:2007-12-01 00:00:00

  • Efficacy of targeted treatment beyond third-line therapy in metastatic kidney cancer: retrospective analysis from a large-volume cancer center.

    abstract:INTRODUCTION/BACKGROUND:Currently, 7 agents are approved for the first- and second-line therapy for metastatic renal cell carcinoma. In contrast, data supporting their use beyond second line are limited. Here we summarize our experience in patients treated with more than 4 lines of therapy. METHODS:We retrospectively ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.12.012

    authors: Vallet S,Pahernik S,Höfner T,Tosev G,Hadaschik B,Duensing S,Sedlaczek O,Hohenfellner M,Jäger D,Grüllich C,Renal Cancer Center at the National Center for Tumor Diseases (NCT) Heidelberg, Germany.

    更新日期:2015-06-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract::Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.3816/CGC.2008.n.023

    authors: Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期:2008-09-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract:BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.12.021

    authors: Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期:2020-08-01 00:00:00

  • A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

    abstract:BACKGROUND:Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clgc.2012.03.002

    authors: Serretta V,Altieri V,Morgia G,Nicolosi F,De Grande G,Mazza R,Melloni D,Allegro R,Ferraù F,Gebbia V

    更新日期:2012-09-01 00:00:00

  • Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.

    abstract:BACKGROUND:The prognostic value of molecular markers in renal cell carcinoma has been investigated in several studies. Although their value is still not confirmed, various proteins are important. We describe the effect on long-term survival of the status of the von Hippel-Lindau (VHL) hypoxia-inducible factor 1-α (HIF1...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2017.05.016

    authors: Salinas-Sánchez AS,Serrano-Oviedo L,Nam-Cha SY,Roche-Losada O,Sánchez-Prieto R,Giménez-Bachs JM

    更新日期:2017-12-01 00:00:00

  • Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors.

    abstract:BACKGROUND:We comprehensively tested contemporary incidence and mortality rates in patients with germ cell tumor of the testis (GCTT). MATERIALS AND METHODS:Within the Surveillance, Epidemiology, and End Results database (2004-2015), statistical analyses included estimated annual percentage changes, multivariable logi...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.06.003

    authors: Palumbo C,Mistretta FA,Mazzone E,Knipper S,Tian Z,Perrotte P,Antonelli A,Montorsi F,Shariat SF,Saad F,Simeone C,Briganti A,Lattouf JB,Karakiewicz PI

    更新日期:2019-10-01 00:00:00

  • Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

    abstract:INTRODUCTION:The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS:Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediat...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.01.018

    authors: Procopio G,Bamias A,Schmidinger M,Hawkins R,Sánchez AR,Estevez SV,Srihari N,Kalofonos H,Bono P,Pisal CB,Hirschberg Y,Dezzani L,Ahmad Q,Rodriguez CS,Jonasch E

    更新日期:2019-06-01 00:00:00

  • Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

    abstract:BACKGROUND:Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients with brain metastases (BM) in a real-world experience. MATERIALS AND ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.05.002

    authors: Peverelli G,Raimondi A,Ratta R,Verzoni E,Bregni M,Cortesi E,Cartenì G,Fornarini G,Facchini G,Buti S,Galli L,Tucci M,Prisciandaro M,Procopio G

    更新日期:2019-08-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract:INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.09.014

    authors: Wu T,Kasper S,Wong RM,Bracken B

    更新日期:2020-04-01 00:00:00

  • Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

    abstract:BACKGROUND:Frontline treatment of metastatic castration-resistant prostate cancer (mCRPC) consists of docetaxel-based chemotherapy. The median time to progression (TTP) from chemotherapy initiation is 6 to 8 months. Ketoconazole, a nonspecific cytochrome P17 inhibitor (CYP17i), blocks adrenal androgen synthesis. Low-do...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2012.11.003

    authors: Gil-Bazo I,Arévalo E,Castillo A,Zudaire ME,Carranza OE,Fusco JP,Castañón E,Collado-Gómez V,López I,Gil-Aldea I

    更新日期:2013-06-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract:BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clgc.2019.10.021

    authors: D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期:2020-02-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract::The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.3816/CGC.2007.n.006

    authors: Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期:2007-03-01 00:00:00

  • Comparison of Patient-Reported Quality-of-Life and Complications in Men With Prostate Cancer, Between Two Modes of Administration.

    abstract:INTRODUCTION:Our purpose was to: (1) assess the level of consistency between the quality-of-life (QOL) scores of men with prostate cancer for urinary/bowel/sexual bother, collected via telephone versus self-administered survey; (2) determine factors associated with variation in level of agreement; and (3) assess the ef...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2015.12.016

    authors: Sampurno F,Ruseckaite R,Millar JL,Evans SM

    更新日期:2016-08-01 00:00:00

  • Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up.

    abstract:BACKGROUND:The purpose of the study was to evaluate the relationships between the patients' clinical characteristics and the growth pattern of SRMs, and to investigate the predictive factors of tumor growth rates in patients initially managed with AS. MATERIALS AND METHODS:We retrospectively reviewed data from our pro...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.08.006

    authors: Schiavina R,Borghesi M,Dababneh H,Bianchi L,Longhi B,Diazzi D,Monti C,La Manna G,Martorana G,Brunocilla E

    更新日期:2015-04-01 00:00:00

  • Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience.

    abstract:INTRODUCTION:Abiraterone improves survival in metastatic castration-resistant prostate cancer (mCRPC) but may result in the development or worsening of comorbid conditions. We assessed the course of these conditions in patients receiving abiraterone in clinical practice and compared outcomes with those in clinical tria...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2019.03.001

    authors: Tsao PA,Estes JP,Griggs JJ,Smith DC,Caram MEV

    更新日期:2019-06-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract:BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clgc.2019.05.001

    authors: Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期:2019-08-01 00:00:00

  • Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

    abstract:BACKGROUND:We investigated the activity of lenalidomide, which has antiangiogenic, antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration-resistant prostate cancer (CRPC) patients. PATIENTS:Patients received 25 mg/d lenalidomide for 21 days in 28-day cycles, until disease progression or una...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2013.09.001

    authors: Nabhan C,Patel A,Villines D,Tolzien K,Kelby SK,Lestingi TM

    更新日期:2014-02-01 00:00:00

  • Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up.

    abstract:INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.04.017

    authors: Elawdy MM,Taha DE,Elbaset MA,Abouelkheir RT,Osman Y

    更新日期:2016-12-01 00:00:00

  • Lymph Node Fluorescence During Robot-Assisted Radical Prostatectomy With Indocyanine Green: Prospective Dosing Analysis.

    abstract:OBJECTIVE:To prospectively assess the ideal dosing and the value of fluorescent sentinel lymph node (LN) detection with indocyanine green (ICG) for the detection of LN metastases in intermediate- and high-risk patients undergoing robot-assisted prostatectomy and extended pelvic LN dissection (ePLND). PATIENTS AND METH...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2016.10.014

    authors: Chennamsetty A,Zhumkhawala A,Tobis SB,Ruel N,Lau CS,Yamzon J,Wilson TG,Yuh BE

    更新日期:2017-08-01 00:00:00

  • Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma.

    abstract:BACKGROUND:The complete remission (CR) rate with salvage systemic therapy for urothelial carcinoma (UC) is unclear, and its value as an intermediate end point and association with survival are unknown. MATERIALS AND METHODS:Data from phase II trials of salvage chemotherapy and/or biologic agents were pooled. Data rega...

    journal_title:Clinical genitourinary cancer

    pub_type: 杂志文章

    doi:10.1016/j.clgc.2014.09.004

    authors: Sonpavde G,Pond GR,Rosenberg JE,Bajorin DF,Regazzi AM,Choueiri TK,Qu AQ,Niegisch G,Albers P,Necchi A,Di Lorenzo G,Fougeray R,Dreicer R,Chen YH,Wong YN,Sridhar SS,Ko YJ,Milowsky MI,Galsky MD,Bellmunt J

    更新日期:2015-04-01 00:00:00